share_log

HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

Benzinga ·  Mar 4, 2023 00:55

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment